Details

Autor(en) / Beteiligte

• Goldman‐Mazur, Sarah
• Jurczyszyn, Artur
• Castillo, Jorge J.
• Waszczuk‐Gajda, Anna
• Grząśko, Norbert
• Radocha, Jakub
• Bittrich, Max
• Kortüm, K. Martin
• Gozzetti, Alessandro
• Usnarska‐Zubkiewicz, Lidia
• Davila Valls, Julio
• Jayabalan, David S.
• Niesvizky, Ruben
• Kelman, Julia
• Coriu, Daniel
• Rosiñol, Laura
• Szukalski, Łukasz
• González‐Calle, Veronica
• Mateos, Maria V.
• Jamroziak, Krzysztof
• Hus, Iwona
• Avivi, Irit
• Cohen, Yael
• Suska, Anna
• Chappell, Aimee
• Madduri, Deepu
• Chhabra, Saurabh
• Kleman, Ariel
• Hari, Parameswaran
• Delforge, Michel
• Robak, Paweł
• Gentile, Massimo
• Kozłowska, Izabela
• Goldberg, Stuart L.
• Czepiel, Jacek
• Silbermann, Rebecca
• Olszewski, Adam J.
• Barth, Peter
• Mikala, Gabor
• Chim, Chor S.
• Długosz‐Danecka, Monika
• Grosicki, Sebastian
• Vesole, David H.

Titel

A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma

Ist Teil von

• American journal of hematology, 2020-05, Vol.95 (5), p.503-509

Ort / Verlag

Hoboken, USA: John Wiley & Sons, Inc

Erscheinungsjahr

2020

Quelle

Wiley-Blackwell Full Collection

Beschreibungen/Notizen

• The t(14;16) translocation, found in 3%‐5% of newly diagnosed (ND) multiple myeloma (MM), has been associated with adverse outcomes. However, the studies establishing the characteristics of t(14;16) included solely small cohorts. The goal of the current international, multicenter (n = 25 centers), retrospective study was to describe the characteristics and outcomes of t(14;16) patients in a large, real‐world cohort (n = 223). A substantial fraction of patients had renal impairment (24%) and hemoglobin <10 g/dL (56%) on initial presentation. Combined therapy of both immunomodulatory drug and proteasome inhibitor (PI) in the first line was used in 35% of patients. Autologous stem cell transplantation was performed in 42% of patients. With a median follow up of 4.1 years (95% CI 3.7‐18.7), the median progression‐free survival (PFS) and overall survival (OS) from first line therapy were 2.1 years (95% CI 1.5‐2.4) and 4.1 years (95% CI 3.3‐5.5), respectively. Worse OS was predicted by age > 60 years (HR = 1.65, 95% CI [1.05‐2.58]), as well as revised International Scoring System (R‐ISS) 3 (vs R‐ISS 2; HR = 2.59, 95% CI [1.59‐4.24]). In conclusion, based on the largest reported cohort of t(14;16) patients, quarter of this subset of MM patients initially presents with renal failure, while older age and the R‐ISS 3 predict poor survival.